21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Symbol: OTCMKTS:ULGX
- CUSIP: N/A
- Web: www.urologix.com
Average Prices:- 52 Week Range: $0.00 - $0.00
P/E:- Trailing P/E Ratio:
- Foreward P/E Ratio: -0.01
- P/E Growth:
Sales & Book Value:- Annual Revenue: $12 million
- Price / Sales: 0.00
- Book Value: ($0.38) per share
- Price / Book: 0.00
Profitability:Misc:- Average Volume: 36,586 shs.
- Beta: 5.35
- Short Ratio: 1.02
Frequently Asked Questions for Urologix (OTCMKTS:ULGX)
What is Urologix's stock symbol?
Urologix trades on the OTCMKTS under the ticker symbol "ULGX."
How were Urologix's earnings last quarter?
Urologix Inc. (OTCMKTS:ULGX) issued its quarterly earnings data on Thursday, February, 5th. The company reported ($0.02) earnings per share for the quarter. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.80 million. View Urologix's Earnings History.
Who are some of Urologix's key competitors?
Some companies that are related to Urologix include Johnson & Johnson (JNJ), Roche Holding (RHHBY), Novartis AG (NVS), Pfizer (PFE), UnitedHealth Group Incorporated (UNH), Merck & Company (MRK), Amgen (AMGN), Sanofi (SNY), AbbVie (ABBV), Medtronic PLC (MDT), Novo Nordisk A/S (NVO), Celgene Corporation (CELG), GlaxoSmithKline PLC (GSK), Gilead Sciences (GILD), Eli Lilly and Company (LLY), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT) and Astrazeneca PLC (AZN).
Who are Urologix's key executives?
Urologix's management team includes the folowing people:
- Gregory J. Fluet, Chief Executive Officer, Director
- Scott M Madson, Chief Financial Officer
- Lisa A. Ackermann, Executive Vice President - Sales and Marketing
- Mitchell Dann, Independent Non-Executive Chairman of the Board, Lead Director
- Christopher R. Barys, Independent Director
- Sidney W. Emery Jr., Independent Director
- Patrick D. Spangler, Independent Director
How do I buy Urologix stock?
Shares of Urologix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Urologix's stock price today?
One share of Urologix stock can currently be purchased for approximately $0.00.
MarketBeat Community Rating for Urologix (OTCMKTS ULGX)MarketBeat's community ratings are surveys of what our community members think about Urologix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Urologix (OTCMKTS:ULGX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Urologix (OTCMKTS:ULGX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Urologix (OTCMKTS:ULGX)Earnings History by Quarter for Urologix (OTCMKTS ULGX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/5/2015 | Q215 | | ($0.02) | $3.80 million | $3.10 million | View | Listen |  |
| 8/19/2014 | Q4 14 | | ($0.17) | | $3.29 million | View | N/A | |
| 2/4/2014 | Q4 | | ($0.05) | | $3.81 million | View | Listen | |
| 11/14/2012 | Q113 | ($0.06) | ($0.05) | $4.48 million | $4.00 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Urologix (OTCMKTS:ULGX)Current Year EPS Consensus Estimate: $-0.21000 EPS
Next Year EPS Consensus Estimate: $-0.23000 EPS
Dividend History for Urologix (OTCMKTS:ULGX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Urologix (OTCMKTS:ULGX)Insider Ownership Percentage: 8.50%
Institutional Ownership Percentage: 0.37%
Insider Trades by Quarter for Urologix (OTCMKTS:ULGX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/26/2013 | Gregory Fluet | CEO | Buy | 17,500 | $0.31 | $5,425.00 | |
| 7/12/2013 | Mitchell Dann | Director | Buy | 20,000 | $0.30 | $6,000.00 | |
| 7/10/2013 | Gregory Fluet | CEO | Buy | 25,000 | $0.24 | $6,000.00 | |
| 7/9/2013 | Lisa A Ackermann | EVP | Buy | 18,500 | $0.24 | $4,440.00 | |
| 7/8/2013 | Gregory Fluet | CEO | Buy | 66,400 | $0.19 | $12,616.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Urologix (OTCMKTS:ULGX)
Latest Headlines for Urologix (OTCMKTS:ULGX)
| Source: |
|
Urologix (ULGX) Chart for Saturday, July, 22, 2017
